NexMed Initiates Enrollment in U.S. Phase I Study of NM10060

NexMed has initiated the U.S. Phase I clinical study for NM10060, the company's proprietary nail lacquer treatment for onychomycosis (nail fungal infection).

The U.S. Phase I study is designed to assess the pharmacokinetic properties, safety and tolerability of NM100060 in 45 patients diagnosed with onychomycosis. The trial design is a double-blind, placebo-controlled study.